A Phase 2 Trial of Capecitabine Concomitantly With Whole Brain Radiotherapy(WBRT) Followed by Capecitabine and Sunitinib for Central Nervous System, (CNS) Metastases in Breast Cancer.

Trial Profile

A Phase 2 Trial of Capecitabine Concomitantly With Whole Brain Radiotherapy(WBRT) Followed by Capecitabine and Sunitinib for Central Nervous System, (CNS) Metastases in Breast Cancer.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Feb 2014

At a glance

  • Drugs Capecitabine (Primary) ; Sunitinib (Primary)
  • Indications Advanced breast cancer; Cancer metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Oct 2012 Planned End Date changed from 1 Dec 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Actual initiation date changed from Dec 2007 to Feb 2009 as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Planned End Date changed from 1 Dec 2015 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top